A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
About this study
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
- Condition
- Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- Tested
- Pirtobrutinib
- Sponsor
- Eli Lilly and Company
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 3
- Minimum age: 18 years
- Study condition: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
Where
38 sites, 38 recruiting
Flinders Medical Centre
Adelaide, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Linear Clinical Research
Victoria, Australia
CHU de Nantes - Hotel Dieu
Nantes, France
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
Bologna, Italy
Ospedale San Raffaele
Milan, Italy
and 32 more sites on ClinicalTrials.gov
Contact
-
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559 LillyTrials@Lilly.com
-
Physicians interested in becoming principal investigators please contact
Potential match only. Final eligibility is determined by the study team.